CD19/CD22 Dual-Target CAR-T Publications
Key publications supporting Hillgene's CD19/CD22 dual-target CAR-T therapy programme for B-cell malignancies and autoimmune indications.
Bispecific CAR Targeting CD19 and CD22
A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignancies. [Protein Cell 2024 · PubMed: 38823002]
Bicistronic CD19/22 CAR-T for Childhood Refractory Lupus Nephritis
Bicistronic-CD19/22 chimeric antigen receptor T-cell therapy for childhood refractory lupus nephritis — demonstrating the translational potential of dual-target CAR-T in autoimmune kidney disease. [Kidney Int Rep 2025 · PubMed: 41541778]
CD19/CD22 CAR-T in Childhood B-ALL
CD19/CD22 CAR T cell therapy in childhood B-cell acute lymphoblastic leukemia — co-administration approach demonstrating durable remission in pediatric patients. [Blood 2024 (ASH) · DOI: 10.1182/blood-2024-204200]
CD19/CD22 CAR-T in Autoimmune Hemolytic Anemia
CD19/CD22-targeted CAR T cells in autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation. [Haematologica 2026 · PubMed: 41852345]
Phase II: Co-Administration of CD19 and CD22 CAR-T in Childhood B-ALL
Single-arm, multicenter Phase II trial of co-administration of CD19- and CD22-directed CAR-T cell therapy in childhood B-cell acute lymphoblastic leukemia — complete remission achieved in 99% of 194 patients. [JCO 2023 · PubMed: 36346962]
Early Predictive Biomarkers for Severe CRS in CAR-T
Identification of early predictive biomarkers for severe cytokine release syndrome in pediatric patients with CAR-T cell therapy — supporting safer clinical management. [Front Immunol 2024 · PubMed: 39328408]
Infectious Complications in Pediatric CD19+CD22+ CAR-T
Infectious complications in pediatric patients undergoing CD19+CD22+ CAR-T cell therapy for relapsed/refractory B-lymphoblastic leukemia. [Int J Clin Pract 2024 · PubMed: 38662121]
Long-Term Outcomes of CD19/CD22 CAR-T in Philadelphia+ B-ALL
Long-term outcomes of co-administration of CD19 and CD22 CAR-T cell therapy in pediatric patients with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. [Front Med 2026 · DOI: 10.3389/fmed.2026.1815353]
Safety of CD19/CD22 CAR-T After CD19 CAR-T Relapse
Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy. [J Transl Med 2023 · PubMed: 36949487]
TCF3-HLF-Positive B-ALL Treated with CAR-T
Successful treatment of TCF3-HLF-positive childhood B-ALL with chimeric antigen receptor T-cell therapy — addressing a rare and aggressive leukemia subtype. [Clin Lymphoma Myeloma Leuk 2021 · PubMed: 33640284]
Durable Remission in TCF3-HLF B-ALL with Dual CD19/CD22 CAR-T
Durable remission achieved in pediatric patients with TCF3-HLF-positive relapsed/refractory B-cell acute lymphoblastic leukemia by dual CD19- and CD22-targeted CAR-T cell therapy. [Haematologica 2025 · PubMed: 40400462]